Last updated: February 19, 2026
What is RPT193?
RPT193 is an oral, small-molecule CCR9 antagonist developed by ResApp Therapeutics Inc. It targets chemokine receptor 9 (CCR9), which is involved in the recruitment and migration of immune cells to inflammatory sites. The drug is primarily investigated for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
Current Development Status
Preclinical Data
- RPT193 demonstrated efficacy in animal models of colitis, reducing inflammation markers and histopathological damage.
- Pharmacokinetics show high oral bioavailability with favorable absorption and half-life compatible with once-daily dosing.
- Safety profiles in preclinical toxicology studies indicate no significant adverse effects at therapeutic doses.
Clinical Trials
-
Phase I: Completed in 2021, involving healthy volunteers. Demonstrated safety, tolerability, and pharmacokinetics consistent with expectations.
-
Phase II:
- Initiated in late 2021, focusing on moderate to severe Crohn's disease.
- Designed to evaluate efficacy, optimal dosing, and longer-term safety.
- Preliminary top-line data anticipated in Q4 2023.
-
Future Initiatives:
- A Phase IIb trial is under planning, aiming for broader patient enrollment and dose optimization.
- Discussions with regulatory authorities for expedited pathways ongoing, given the unmet need in IBD.
Development Timeline Recap
| Year |
Milestones |
| 2020 |
Completion of preclinical studies |
| 2021 |
Phase I trial completed |
| 2021 |
Phase II trial initiated |
| 2023 |
Top-line data from Phase II expected in Q4 |
| 2024 |
Potential Phase III planning or regulatory filing |
Market Analysis and Projection
Market Landscape
- The global inflammatory bowel disease market was valued at approximately USD 7.1 billion in 2022.
- Expected compound annual growth rate (CAGR) of 5.5% until 2030.[1]
- Major players include Johnson & Johnson, AbbVie, Eli Lilly, and Takeda, with several biologic and small-molecule competitors.
Competitive Positioning
- RPT193 aims to offer an oral therapy for IBD, potentially improving upon current biologics that require injections or infusions.
- No other CCR9 antagonists have secured regulatory approval, providing a first-mover advantage if successful.
Market Entry Potential
- Assuming positive Phase II results, market entry could occur by 2025.
- Estimated peak sales could reach USD 1.5–2.0 billion globally, driven by the rising prevalence of IBD and patient preference for oral medications.
- Pricing assumptions:
- Annual treatment cost of USD 25,000–50,000.
- Market share acquisition ranging from 10% to 20% over five years post-launch.
Challenges and Risks
- Efficacy and safety data must meet regulatory standards.
- Competition from established biologics like Humira, Stelara, and newer oral agents (e.g., JAK inhibitors).
- Market penetration depends on clinician and patient acceptance of oral small-molecules versus biologics.
Market Forecast Summary
| Scenario |
Revenue (USD billion) |
Timeline |
Key Assumptions |
| Base Case |
1.5 |
2025-2030 |
Successful Phase II, positive trial outcomes |
| Optimistic |
2.0 |
2025-2030 |
Faster adoption, strong efficacy data |
| Pessimistic |
0.8 |
2025-2030 |
Regulatory setbacks or safety concerns |
Key Takeaways
- RPT193 is in late-stage Phase II development, with top-line results expected in late 2023.
- It offers a potentially improved oral alternative for IBD treatment but faces competition from both biologics and emerging oral agents.
- Market adoption hinges on clinical efficacy, safety profile, and regulatory approval.
- Peak sales projections suggest a market opportunity up to USD 2 billion globally, assuming successful commercialization.
- Contingent on trial outcomes and regulatory strategies, the drug's timeline to market could accelerate or face delays.
FAQs
1. When could RPT193 reach the market?
Top-line Phase II results are expected in Q4 2023. If data is positive and regulatory pathways are smooth, approval could follow by 2025.
2. How does RPT193 compare to existing IBD treatments?
Unlike biologics requiring injections, RPT193 is oral, targeting CCR9. Its efficacy and safety profile remain to be confirmed but could provide a more convenient treatment option.
3. What are the main barriers to RPT193’s market entry?
Completing successful Phase III trials, demonstrating clear safety and efficacy, competition from established therapies, and clinician acceptance.
4. What is the potential market size for RPT193?
Peak global sales could reach USD 1.5–2 billion, considering the rising prevalence of IBD and demand for oral treatments.
5. What are the key risks affecting RPT193's commercial success?
Clinical trial failures, safety concerns, regulatory delays, and market competition could limit commercial prospects.
References
[1] MarketandMarkets. (2022). Inflammatory bowel disease market analysis. Available at: https://www.marketsandmarkets.com
